InterviewPilar de la Huerta
In September 2014, Sygnis AG, specialized on the development and commercialization of products for DNA amplification and sequencing, announced that it will expand its established licensing business by adding an own portfolio of proprietary kits for the molecular biology market.
Seite [1 von 1]
 | | | Bild 1 von 1 | | | |
Before joining Genetrix as CEO in 2010, Pilar de la Huerta has successfully held executive roles in biotech companies over the last 15 years. Following the merger with X-Pol Biotech, a subsidiary of Genetrix, she became CEO/CFO of Sygnis AG in December 2012.